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Background: Metabolic syndrome (MetS) is a multifactorial disease, whose main stay of
prevention and management is life-style modification which is difficult to attain.
Combination of herbs have proven more efficacious in multi-targeted diseases, as
compared to individual herbs owing to the “effect enhancing and side-effect
neutralizing” properties of herbs, which forms the basis of polyherbal therapies This led
us to review literature on the efficacy of herbal combinations in MetS.
Methods: Electronic search of literature was conducted by using Cinnahl, Pubmed
central, Cochrane and Web of Science, whereas, Google scholar was used as
secondary search tool. The key words used were “metabolic syndrome, herbal/poly
herbal,” metabolic syndrome, clinical trial” and the timings were limited between
2005–2020.
Results: After filtering and removing duplications by using PRISMA guidelines, search
results were limited to 41 studies, out of which 24 studies were evaluated for combinations
used in animal models and 15 in clinical trials related to metabolic syndrome. SPICE and
SPIDER models were used to assess the clinical trials, whereas, a checklist and a
qualitative and a semi-quantitative questionnaire was formulated to report the findings
for animal based studies. Taxonomic classification of Poly herbal combinations used in
animal and clinical studies was designed.
Conclusion: With this study we have identified the potential polyherbal combinations
along with a proposed method to validate animal studies through systematic qualitative
and quantitative review. This will help researchers to study various herbal combinations in
MetS, in the drug development process and will give a future direction to research on
prevention and management of MetS through polyherbal combinations.
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INTRODUCTION
Non-communicable diseases (NCDs) account for 71% of the
deaths worldwide with rising prevalence in lower- and middle-
income countries (Huang, 2009; Robinson et al., 2013). NCDs
have been ranked as one of the top ten global threats in 2019 by
World Health Organization (Khowaja et al., 2007; Robinson et al.,
2013). Metabolic syndrome (MetS) is a type of NCD with
worldwide prevalence ranging from less than 10% to as much
as 84% (Rhee et al., 2010) with the burden being greater in South
Asian countries (Sever et al., 2003; Su and Li, 2011).
MetS is characterized by a cluster of three or more features
including hyperglycaemia, hypertriglyceridemia, a low level of
high-density lipoprotein cholesterol (HDL-C), blood pressure
and central obesity (Bodeker and Kronenberg, 2002; Anderson
and Taylor, 2012). A person who has at least three out of five of
these characteristics is labelled as MetS patient. The following
criteria should be met for MetS (AuH, 1998; Anderson and
Taylor, 2012): waist circumference more than 35 and 40
inches in women and men, respectively (central obesity);
triglycerides (TGs) 150 mg/dl or greater, HDL-C less than 50
and 40 mg/dl in women and men, respectively, blood pressure
(BP) of 130/85 mm Hg or higher, fasting blood glucose (FBG) of
100 mg/dl or greater. Besides the above mentioned abnormalities,
underlying initiators of MetS are inflammation, oxidative stress
and insulin resistance (Ma et al., 2009; Aziz et al., 2013; Amin
et al., 2015a). Together these factors pose a three- and five-fold
greater risk for cardiovascular disease (CVD) and type II diabetes
mellitus (T2DM) respectively (Zimmermann et al., 2007), along
with high mortality rate (Gilani and Rahman, 2005).
MetS has multiple aetiologies and therefore no single drug can
be effective in reversing this situation. The main stay of
prevention and management of individuals at risk is life-style
modification. However, those who have high levels of risk factors
are the recipients for pharmacological treatment which is aimed
towards individual symptoms’ management (AuH, 1998;
Devalaraja et al., 2011; Mohamed, 2014). Multiple drugs
including drugs to lower the blood glucose level, TGs, and
blood pressure (Robinson et al., 2013) may be needed for a
long time resulting in drug related complications, low
compliance rate and high cost of care (Khowaja et al., 2007;
Huang, 2009). Alternately, some researchers suggest to advocate
life-style modification as the first line therapy for prevention of a
chronic disease, rather than using pharmacological therapies such
as metformin in pre-diabetes (Rhee et al., 2010) and statins in
mild to moderate dyslipidemia (Sever et al., 2003). Endorsing
only life-style modifications is challenging for the physicians
especially among high-risk patients such as in obese patients,
since compliance to dietary modification, and physical activity is
difficult to attain (Samir et al., 2011). Therefore, it is imperative to
explore innovative therapies which are cost-effective and
acceptable, with fewer adverse effects, in order to reduce the
risk of cardiovascular diseases (CVD) through addressing the risk
factors.
According to World Health Organization (WHO), up to 80%
of the Asian population relies on complementary and alternative/
Traditional medicine (CAM/T) for their primary healthcare,
possibly because more than 80% of people in developing
nations can barely afford basic medical needs (Su and Li,
2011). Interestingly, almost half of the population in the
developed world also uses CAM/T therapies (Bodeker and
Kronenberg, 2002). Amongst the most common
complementary modalities used by individuals with CVD risk
factors are natural products (Anderson and Taylor, 2012) that
have evidently contributed in the development of modern
medicine for cardiovascular disorders (AuH, 1998). MetS
requires multiple factors to be addressed simultaneously,
therefore polyherbal combinations can offer a safe and more
effective therapeutic option. Research has revealed that the multi-
component properties of polyherbal combinations make them
suitable for treating complex diseases and offer great potential for
exhibiting synergistic actions. Evaluation of literature from
individual effects of potential polyherbal combinations paves
the path for deriving new combinations.
Synergistic therapeutic actions of polyherbal formulations are
possible through underlying mechanisms such as regulation of
same or different targets in various pathways hence in
combination enhance efficacy, regulation of enzymes and
transporters to improve oral drug bioavailability, neutralize
adverse effects and overcome drug resistance mechanisms.
Synergism is observed when multiple chemical constituents are
present in single or in combination of herbs (Amin et al., 2015a),
which are potential therapeutic options for various disease
targets. This forms the basis of polyherbal therapies (Ma et al.,
2009; Aziz et al., 2013) and is considered rational and more
efficacious in multi-targeted diseases (Zimmermann et al., 2007).
The effect-enhancing and side-effect neutralizing properties of
polyherbal combinations (Gilani and Rahman, 2005) prompted
us to review the literature on the efficacy of polyherbal
combinations in metabolic syndrome, the incidence of which
is rising globally. This will help researchers to identify various
effective polyherbal combinations in MetS, which may help in the
drug development process, as well as provide future direction
towards research on prevention and cure of a menace like
metabolic syndrome. Although synergistic therapeutic
interactions of herbal ingredients have been frequently
reported, to the best of our knowledge, none of the reports
have offered review of polyherbal formulations in MetS.
Individual herb reviews related to MetS were limited to
functional foods (Mohamed, 2014) and exotic fruits
(Devalaraja et al., 2011). Hence, in this review, we present
recent literature reporting herb synergisms and efficacy of
various polyherbal formulations in MetS. We have identified
the herb to be good if it manages to modulate at least 3 out of
5 MetS criteria.
METHODS
Systematic Review Protocol (Search
Strategy and Data Sources)
We decided for a qualitative systematic review for which an
electronic literature search was carried out to find articles
published mainly in the last 15 years (2005–2020).
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For this purpose, following databases, and/or search engines
were used: Cinnahl, Pubmed central, Cochrane, Web of Science
and Scopus. Google scholar was used as secondary search tool.
The key words used were “metabolic syndrome, herbal/
polyherbal,” “metabolic syndrome, clinical trial”.
Inclusion Criteria
1. Animal model with MetS that are given more than one herb
for treatment.
2. Adults diagnosed with MetS (who qualify for 3 of the 5 MetS
parameters: obesity, high blood pressure,
FIGURE 1 | Summary of literature search (A) and Analysis of systematic review results according to Prisma guidelines (B).
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Turmeric Curcuma longa L. Zingiberaceae C. longa
Kalonji/black seeds Nigella sativa L. Ranunculaceae N. sativa
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hypertriglyceridemia, low HDL, high blood sugar
(>100–125 mg/dl).
3. Adults >17 years < 74 years.
Exclusion Criteria
1. Review article.
2. Effect of individual herbs on MetS
3. Effect of interventions through diet, low caloric,
mediterranean diet etc., on MetS.
4. Any MetS model used but not for the purpose of assessing
effect on MetS, rather individual aspect such as obesity, non-
alcoholic fatty liver disease and non-alcoholic steatohepatitis
and polycystic ovary syndrome.
Data Analysis and Study Design
All the polyherbal formulations were classified taxonomically and
then effect of intervention and evaluation of results were done,
based on number of MetS criteria met both in animal and/or
humans.
Quality of animal-based studies were assessed by using a
qualitative scoring system using 8 questions. Maximum score
achieved was 8, with yes  score 1 and no  score 0 with following
questions:
1. MetS parameters assessed >3  score 1; ≤3  score 0
2. MetS parameters met: 3 out of 5 parameters (good Effect)  1;
<3 out of 5 (not so good)  0.
3. Dosage of herb provided: Yes  1; No  0
4. Components and rationale for dosing: yes  1; no  0
5. Animal ethical approval: Yes  1; No  0
6. Euthanasia protocol mentioned/followed: Yes  1; No  0
7. Model validated for MetS: Yes  1; No  0
8. Positive control used: Yes  1; No  0
For clinical trial we adopted a mixed model for assessing
our articles including SPICE (S  setting; P  population;
I  intervention/what; C  comparison/controls E 
evaluation/with what result) (Booth, 2006; Cleyle and Booth,
2006) and SPIDER (S  Sample P  phenomenon of interest/
intervention I  intervention size, D  design, E  evaluation/
outcome R  research type; qualitative, quantitative or mixed
type). SPIDER methods had added points for assessing both
qualitative and quantitative methods (Cooke et al., 2012).
Further aspects of quality of clinical trial were assessed
based on following aspects with yes  1; No  0 according
to an adopted guideline for critical appraisal (Alcántara et al.,
2011):
1. The study addresses an appropriate and clearly focused
question
2. The assignment of subjects to treatment groups is
randomized.
3. An adequate concealment method is used
4. The design keeps subjects and investigators ‘blind’ about
treatment allocation.
5. The treatment and control groups are similar at the start of
the trial.
6. The only difference between groups is the treatment under
investigation.
7. All relevant outcomes are measured in a standard, valid and
reliable way
8. What percentage of the individuals or clusters recruited into
each treatment arm of the study dropped out before the study
was completed?
9. All the subjects are analyzed in the groups to which they were
randomly allocated (often referred to as intention to treat
analysis)
10. Where the study is carried out at more than one site, results
are comparable for all sites.
Besides, following questions were also assessed:
concentration of the herb provided or not, quality control
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TABLE 2 | Taxonomic classification of all the polyherbal combinations used in clinical studies against metabolic syndrome.
S.
No
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Vitamin E α- tocopherol
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TABLE 2 | (Continued) Taxonomic classification of all the polyherbal combinations used in clinical studies against metabolic syndrome.
S.
No
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Turmeric
Berberis aristate DC. Berberidaceae B. aristata
Colocynth, Bitter apple,
wild gourd
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TABLE 2 | (Continued) Taxonomic classification of all the polyherbal combinations used in clinical studies against metabolic syndrome.
S.
No
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Orthosiphon stamineus Benth Lamiaceae O. stamineus
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Cuban sugar cane wax
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Red yeast rice extract
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Red yeast rice (obtained
by culturing the yeast
Monascus purpureus
on rice) and olive extract
red yeast rice (Purple
fermented rice,





olive extract Olea europaea L Oleaceae O. europaea
13 He et al.
(2007)
Yiqi Sanju Formula Details not available as
paper is in Chinese







Red yeast rice, bitter
gourd, chlorella, soy
protein, and licorice
Red yeast rice Monascus purpureus, (Went,
1895)
Monascaceae M. purpureus
Bitter gourd Momordica charantia L Cucurbitaceae M. charantia
Green algae Chlorella Chlorellaceae
Soy protein (isolated
from soybean)
Glycine max (L.) Merr Fabaceae G. max
Licorice Glycyrrhiza glabra L Fabaceae/
Leguminosae
G. glabra
(Continued on following page)
Frontiers in Pharmacology | www.frontiersin.org October 2021 | Volume 12 | Article 75292612
Palla et al. Polyherbals in Metabolic Syndrome
of the combination assessed or not and chemical
classification done or not.
RESULTS
The selection parameter, applied filters, as well as output of all the
searches, are summarised in Figure 1A. In Figure 1B the
summary of identified results is presented according to
PRISMA guidelines (Page et al., 2019; Maraolo, 2021).
The total reference shortlisted were 109, out of which
duplications and or articles which could not be retrieved
were removed (n  15) and number of articles to review
were 94. Out of total 94 articles, 26 were divided as clinical
trials and remaining 68 articles were either based on animal
studies or in-vitro assays. These articles were further shortlisted
by reviewing their basic theme and it was identified that some of
the articles did not have the objective to manage MetS or were
aimed at identifying new targets for management of Met S such
as use of probiotics or correlating with gut microbiota (Ni et al.,
2018) or the basic target for those studies were to cater different
disease, although parameters for MetS were being met. Hence,
out of 68 animal studies, filtered animal studies were identified
to be 24 which matched our main objective of MetS. The
taxonomic classification of polyherbal combinations used
both in animal and clinical studies are summarized in Tables
1, 2, respectively. The meta-analysis of animal studies is
summarized in Table 3. To further analyze the quality of
studies, a semiquantitative scale was used, the details of
which are presented separately as Table 4. The maximum
score was 8, and references have been aligned from highest
score to lowest score.
Out of 26 clinical trial articles, 15 articles matched our main
objective, and their meta-analysis is presented in Table 5
according to SPIDER model with references. Supplementary
Table S1 is attached to shows the analysis by SPICE protocol
along with information about other targets met besides the 5
parameters of MetS. Table 6 summarizes the qualitative scoring
based on a checklist as mentioned in analysis section along with
the online link available for the same. Out of 15 polyherbal
combinations that were reviewed three formulations were able to
modify 4 MetS parameters clinically. They include Yiqi Huazhuo
Gushen herbal formula (Tian-zhan et al., 2019), Yiqi Huaju
Qingli Formula (Wang et al., 2013), Sesame oil and vitamin E
(Farajbakhsh et al., 2019). Six polyherbal combinations were able
to reduce three out of 5 standard MetS parameters. The
combinations included, Curcuma longa and Nigella sativa
(Amin et al., 2015b), Diabegon (Yadav et al., 2014), modified
Lingguizhugan decoction (MLD)+ weekend fasting (Yang et al.,
2014a), Dahuang Huanglian Xiexin Decoction (Yu et al., 2018),
combination of Nutraceuticals (Rozza et al., 2009) and Altilix
supplement containing chlorogenic acid and luteolin (Castellino
et al., 2019).
DISCUSSION
MetS is a cluster of metabolic abnormalities that appear as a pre-
diseased state and predisposes to CVD risk even before overt
disease such as diabetes or hypertension develops. Catering those
risk factors at this stage could prevent incidence of CVD. Hence,
clinicians need to target multiple risk factors simultaneously. As
the incidence of MetS is rising, there is a need to identify
therapeutic modalities that could address multiple disease
targets, offer better compliance, and reduce risk of adverse
effects (Reilly and Rader, 2003; Keith et al., 2005). Polyherbal
formulations could mutually enhance pharmacological synergy
on the targeted disease and often exhibit pharmacological and
therapeutic superiority in comparison to isolated single
constituents.
The current review focuses on studies published from
2005–2020, reporting the efficacy of polyherbal therapies in
MetS. This is attributed to either the action of bioactive
ingredients from different herbs on the same molecular
target forming a multiple-drug-one-target model (additive
effect) and/or the functionally diverse targets but with
potentially clinically relevant associations forming a
multiple-drug-multiple-target-one-disease (synergistic effect)
(Lu et al., 2012; Wang et al., 2012). In the current review, we
identified 25 animal based studies in which polyherbal
formulations were used in animal models of Mets. We
categorised them as good and not very good, based on the
TABLE 2 | (Continued) Taxonomic classification of all the polyherbal combinations used in clinical studies against metabolic syndrome.
S.
No




















Cinnamomum verum J.Presl Lauraceae C. veruum
Shaoyao Paeoniae Radix; Peony
root; Chinese peony
Paeonia lactiflora Pall Paeoniaceae P. lactiflora




Taoren Persicae Semen; fruit
kernel of Peach
Prunus persica (L) Batsch Rosaceae P. persica
Fuling Hoelen (dried sclerotia
of Wolfiporia cocos;
Wolfiporia cocos (F.A. Wolf)
Ryvarden & Gilb
Polyporaceae W. extensa
Frontiers in Pharmacology | www.frontiersin.org October 2021 | Volume 12 | Article 75292613
Palla et al. Polyherbals in Metabolic Syndrome
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Assessed: 5/5  Body weight,
abdominal waist, BP, glucose, TG,
HDL-C, TC, LDL and VLDL. Met: 5/5
 Lowered Body weight, abdominal
waist and BMI, reduced BP, AI,
improved FBG and OGTT, reduced
TG, increased HDL-C. Also, TC, LDL
and VLDL reduced
Reduced SGOT, SGPT, Uric acid,
MDA. Reduced gastrocnemius
muscle weight and fat pads.
Reduced infiltration of inflammatory
cells and fat accumulation in liver and
pancreas












(80 g), Prunus persica
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Cinnamomum cassia





Assessed: 5/5  Body weight, BP,
TG, HDL, Glucose. TC and LDL, Met:
5/5  Reduced body weight
(Reduced liver weight and adipose
tissue mass, adipocyte size), BP, TG,
glucose and increased HDL-c. TC
and LDL-c reduced
Decreased serum leptin and leptin
mRNA expression. increased mRNA
expression of peroxisome proliferator
activated receptor-gamma,
uncoupling protein-2, and
adiponectin in visceral adipose tissue
of HFD mice. Inhibition of porcine
pancreatic lipase and ACE activities
in vitro










10% sucrose, 6% salt






Assessed: 5/5  BP, body weight,
FBG, fasting insulin, and insulin
resistance index, TG, HDL-C, LDL-c.
Met: 5/5 = Reduction in body weight,
BP, FBG, fasting insulin and insulin
resistance index, TG levels reduced,
and HDL-c increased. LDL-C
reduced
inhibited the activation of NF-kB and
reduced serine phosphorylation of
IRS-1
1 1 Yes Yes No Li et al.
(2013)





Assessed: 5/5  body weight,
Glucose, BP, TG, HDL-c. TC and
LDL-c. Met: 5/5  Reduced body
weight and epididymal fat pads
weight, reduced TG, systolic BP and
increased HDL-c, OGTT improved.
TC and LDL-c reduced
reduced leptin, CRP and glutamic-
oxaloacetic transaminase,
Decreased VCAM-1, ICAM-1, E
selectin, MCP-1 and improved
PPAR-γ expression. lipid droplets in
liver decreased





















HFD for 12 weeks
(30% HFD + dietary
restriction ± 45 min
swim)/adult SD male
rats/1 week after HFD
for subsequent
12 weeks
Assessed: 5/5  body weight, TG,
HDL, BP, blood glucose. Met: 5/5 
reduced body weight, TG, BP, blood
glucose and insulin levels, Increased
HDL. Reduced TC, LDL, adipose and
liver tissue weight
Reduced serum FFA, AST, ALT and
ALP and TNF-α, leptin in serum and
liver
1 1 Yes Yes Yes Yao et al.
(2017b)









































5 = glucose/FBG, TG, HDL-C, BP
and central obesity (weight, BMI,
HC and WC). Parameters met:
BMI [WC, HC], BP, HDL, TG, FBG.
Additional: TC, LDL










1; <3/5 (not so








6 Curcuma longa and
Nigella sativa
Fructose fed rats (60%
fructose in diet + white
flour instead of wheat
flour) for 6 weeks/SD
rats/6 weeks
Assessed: 5/5  body weight, BP,
Fasting serum insulin, FBG, HDL, and
TG, Met: 4/5  Reduced BP, TG,
FBG, increased HDL. Reduced LDL,
TC and insulin
CRP reduced 1 1 Yes No Yes Amin et al.
(2015a)







Assessed: 4/5  Body weight, TC,
TG, HDL and glucose. Met: 4/5 
Reduced weight gain (reduced liver
weight and fat), FBG and insulin, TG
and Increased HDL. Reduced TC
and LDL.
Reduced food intake, ALT,
GGT, ALP
1 1 Yes No but the diet
was purchased
commercially








Assessed: 4/5  Body weight, TG,
FBG, HDL-C (TC and LDL-c). Met: 4/
5  Reduced body weight (reduced
liver weight, epididymal,
retroperitoneal, and visceral adipose
tissues. Reduced adipocyte size, TC
and TG in liver), reduced serum TG,
FBG and increased HDL. Reduced
LDL-c and TC
PPAR-γ, fatty acid synthase;
SREBP-1c; and PPAR-α
1 1 Yes Yes Yes Lee et al.
(2015b)
9 Fu Fang Zhen Zhu






















Assessed: 4/5  Body weight, FBG,
TG, HDL-c, TC. Parameters met: 4/5
 Reduced body weight, FBG
(HOMA-IR index), TG increased
HDL-c. reduced TC.
Increased PI3K p85 mRNA
expression in the adipose tissues.
Reduced glucose content, PI3K p85
mRNA and IRS1 protein expression
upregulated in insulin resistant
HepG2 cells






(9 g), Poria (6 g) and
Radix
Glycyrrhizae (3 g)
HFD for 10 weeks/
Male C57BL/6J mice/
4 weeks
Assessed: 4/5  glucose, TG, HDL,
obesity, Met: 3/5  reduced Body
weight, Abdominal circumference,
FBG and improved OGTT, no effect
on insulin levels. Reduced TG but no
effect on HDL-c and LDL-c.
Reduced TC.
Increased CDKAL1 expression in the
liver, visceral and subcutaneous
adipose tissues increased, improved
islet cell function to secrete more
insulin
1 0 Yes No No Gao et al.
(2015)









































5 = glucose/FBG, TG, HDL-C, BP
and central obesity (weight, BMI,
HC and WC). Parameters met:
BMI [WC, HC], BP, HDL, TG, FBG.
Additional: TC, LDL










1; <3/5 (not so
















Assessed: 4/5  body weight,
Glucose, TG, HDL (LDL and TC also
assessed), Met: 3/5, improved
glucose tolerance, reduced TG and
increased HDL. LDL-c and TC
reduced
Increased catalase, glutathione, and
SOD. Decreased granular
degeneration in diabetic liver
1 1 yes yes Yes Gao et al.
(2015)





Assessed: 4/5 =Body weight, Serum
glucose levels, TG, HDL-c (TC, and
LDL-C). Met: 3/5  Reduced serum
TC, TG, body weight (reduced
visceral fat mass), glucose, enhanced
insulin sensitivity. TC and LDL-c
reduced
Reduced Serum non-esterified fatty
acids, ALT and AST, adipokines,
TNF-α and IL-6. Increased leptin in
adipose tissue. Enhanced leptin
expression




















15% saturated fat and
40% sucrose; Cell line:
3T3-L1 preadipocyte/
Mice/4 weeks
Assessed: 3/5  Body Weight, TG,
HDL-c. also TC, Met: 2/5  Reduced
TG, increased HDL-c. Also
reduced TC
Reduced CETP, vLDL-c and TGs.
Stimulated lipolysis and inhibited
adipogenesis in 3T3-L1 cells



























dissolved in 1ml of
distilled water per
100 g of body weight
for 1 day (Acute model)
Assessed: 4/5  obesity with marked
visceral fat, blood glucose, HDL and
BP, Met: 2/5  Lowered Body
weight, obesity, BP. LDL reduced.
No effect on non-FBG, TC, HDL.
Food intake reduced; White adipose
tissue (weight and cell size
decreased); expression of genes
increased: adiponectin and PPAR
receptors; reduction in plasma
acylated-ghrelin genes expression
(antihypertensive effect)

















































5 = glucose/FBG, TG, HDL-C, BP
and central obesity (weight, BMI,
HC and WC). Parameters met:
BMI [WC, HC], BP, HDL, TG, FBG.
Additional: TC, LDL










1; <3/5 (not so

















and WKY rats for
control/male rat
7 weeks/)/low and high
dose 2 weeks
Assessed: 4/5  BP, sugar, SBP,
bodyweight and fat, TG, Met: 4/5 
reduced SBP, body weight and fat
mass, FBG, insulin levels. Insulin
resistance (OGTT and ITT) was
reduced. TC levels did not reduce
significantly
AST, ALT, FFA reduced. Gene
expression of NAD+ -dependent
deacetylase E10 and genes related
to fatty acid oxidation were markedly
up- regulated in the muscle, liver and
adipose tissues



















ternata (6g ) and Caulis
Bambusae (6g)
High-sugar-fat-diet
(15 weeks) and high-




perimeters, serum insulin HOMA-IR,
HDL. Met: 3/5  decrease in
abdominal perimeters and serum
insulin levels, increases in HDL levels,
Recovered the HOMA-IR to the
control level
pathway analysis and molecular
docking simulation










Assessed: 4/5  weight gain, FPG
and glucose intolerance, insulin
sensitivity, TG, HDL (LDL also
assessed). Met: 2/5  reduced TG,
FPG, glucose intolerance and Insulin
sensitivity index, LDL/HDL ratio and
TC levels also reduced
Mitochondrial coupling efficiency of
skeletal muscle was improved and
reduced carnitine palmitoyl CoA
transferase activity



















Assessed: 3/5 = Body weight, FBG,
TG, TC. Parameters met: 3/5 
Lowered body weight, visceral fats,
TG, slightly reduced FBG. (Reduced
insulin level and NAFA, improved
impaired glucose tolerance and
glucose infusion rate). TC reduced
Enhanced GLUT4 expression in
adipose tissue, enhanced insulin
mediated glucose uptake in red
quadriceps and white gastrocnemius
skeletal muscles, enhanced
glycogen synthesis
0 1 No (but yield is




Yes Yes Tan et al.
(2011)











Assessed: 4/5  weight gain, FBG,
TG, HDL-c. Met: 3/5 Reduced FBG
and TG and increased HDL-c.
Reduced insulin levels, insulin
resistance (IR) and lSI
Upregulation of Carboxylesterase
and retinal guanylate cyclase 2
precursors. Downregulation of IgG,
carnitine acetyltransferase, tubulin
beta 5, and Gan Lu sugar binding
protein C. protein tyrosine kinase,
beta glucosidase
1 1 No No No Liu and Shi,
(2015)









































5 = glucose/FBG, TG, HDL-C, BP
and central obesity (weight, BMI,
HC and WC). Parameters met:
BMI [WC, HC], BP, HDL, TG, FBG.
Additional: TC, LDL










1; <3/5 (not so

















Assessed: 3/5  Glucose and insulin,
TG and TC levels. Parametersmet: 3/
5  Reduced glucose levels and
insulin levels (HOMA-IR index
reduced), Reduced TC and TG.
Regulated adipogenic gene
expression, proteins involved in
energy metabolism (in maturated
3T3-L1 cells). Increased
phosphorylated AMP activated
protein, as well as attenuated insulin
resistance and hepatic steatosis,
improved glucose facilitation by
GLUT2 externalization. in FFA-
induced steatotic HepG2 cells
0 1 Yes No No Lim et al.
(2019)
21 Marjoram and chicory
Marjoram dry leaves
(Origanum majorana)
and chicory dry leaves
(Cichorium intybus) (1:
5 w/v in water)
HFD/female SD albino
rats/4 weeks
Parameters assessed: 3/5  Body
weight gain, TG, HDL-c (Additional:
TC, LDL-c, VLDL-c, adipose tissue
weight). Parameters met: 3/5 =
lowered weight gain (Adiposity index
and FER), reduced TG, and
increased HDL-c; Adipose tissue
weight, TC, LDL-c, VLDL-c also
reduced
decreased ALT and AST. increased
serum free T4 and T3 hormones



















mice (4 weeks old)/
8 weeks
Assessed: 4/5  Body weight
Glucose, TG, HDL Met: 2/5 =
Reduced body weight, FBG, insulin
levels, Improved OGTT. No effect on
HDL. Decrease in TC, liver and fat
weight
serum inflammatory and hepatic
enzyme levels diminished.
suppressed lipid accumulation







HFD and Cell lines:
3T3-L1, Caco-2 and
HepG2 cell line/C57Bl/
6 male mice/8 and
12 weeks
Assessed: 4/5  body weight (fat pad
weight to body weight ratios; liver
weight to body weight ratios); TG,
glucose, insulin. TC, LDL-c also
assessed. Met: 1/5  reduced diet-
induced increase in body weight and
fat pad mass, reduced diet-induced
increase in liver weight, liver lipid, and
plasma lipid. No Effect on glucose
and insulin. reduced liver TC and TG.
Reduced TC and LDL-c
Improved Plasma adiponectin level,
reduced inflammation (reduced mac-
3 expression) in liver. Inhibitory
effects on 3T3-L1 preadipocytes
differentiation inhibited the glucose
uptake Inhibited fatty acid uptake
prevented the cholesterol uptake
0 0 Yes Yes Yes Wat et al.
(2018)

































modulation of MetS parameters. Studies which were able to
modulate 4-5 parameters were considered as very effective,
whereas studies that modulated three or less than 3 parameters
were marked as not so good. This, however, does not reflect on
the quality of review. For the quality of review, we devised an 8-
question checklist and marked one point for meeting the
criteria and 0 for no meeting the criteria. The overall score
was 8.
From the effect point of view, different combinations were
identified as very effective in animal based studies. They included
combination of Curcuma longa, Salacia reticulate, Gymnema
sylvestre, Emblica officinalis, Terminalia chebula (Thota et al.,
2014), Glycyrrhizae uralensis Fischer, Rheum undulatum Linne,
Prunus persica Linne, Cinnamomum cassia Presl andNatrii Sulfas
(Sung et al., 2014), Rhizoma coptidis, Radix scutellariae, Cortex
phellodendri and Fructus gardeniae (Li et al., 2013), Red ginseng
and Polygoni Multiflori Radix (Kho et al., 2016) and modified
lingguizhugan decoction (Yao et al., 2017a). These combinations
modulated all the five parameters of MetS including reduction in
body weight/obesity, BP, TG, and fasting blood glucose (FBG)
and increase in HDL. Additionally, combination of soybean meal
and probiotics (Bifidobacterium longum) (Mounts et al., 2015), Fu
Fang Zhen Zhu Tiao Zhi formula (Hu et al., 2014), Curcuma
Longa and Nigella Sativa (Amin et al., 2015a) and mixed extracts
of Artemisia iwayomogi and Curcuma longa (Lee et al., 2015a)
improved 4/5 MetS parameters and can be further considered for
clinical trials.
These studies however exhibited certain limitations. For
example, Lee et al. (2015a), comprehensively studied effect of
Artemisia iwayomogi and Curcuma longa extract on
metabolic markers along with fine mechanistic details but
did nto use positive controls in their study. Similarly, Yao
et al. (2017a) did not use positive controls in their study when
studying effect of modified Lingguizhugan decoction (MLD)
and only selected one dose for intervention. Hence, dose
dependent effect couldn’t be assessed. Besides, they did not
study the effect mediated by MLD alone and only showed
results of MLD with dietary restriction and exercise;
additional group of MLD should have been added for
confidently claiming the effect of MLD in the study. Amin
et al., presented their findings comprehensively about use of
combined Curcuma longa and Nigella sativa in MetS models
but despite of mention of measuring body weight fortnightly,
there were no results about effect on body weight (Amin et al.,
2015a).
Some studies showed reduced effect on Met S parameters,
but their focus was more on mechanistic details. For instance,
study by Gao et al. (2015) on effect of Erchen decoction (ECD)
exhibited effect on 3 parameters of MetS including FBG, TG
and body weight and abdominal circumference. One of the
appreciable aspects of this study is that the researchers
reported abdominal circumference and body weight
simultaneously. Limited animal studies consider abdominal
circumference, which is the actual predictor of MetS.
Additionally, molecular mechanisms of ECD on diabetic
parameters have been elaborated at genetic level, where
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like 1 (CDAK1) has been shown and correlated with improved
islet cell function. Since this preparation did not have effect on
LDL and HDL, combining it with antidyslipidemic herb, such
as Curcuma longa and/or Nigella sativa coupled with low dose
of ECD may be a good combination for future studies. Like
this, extracts of Salvia miltiorrhiza and Gardenia jasminoides
(Tan et al., 2013), showed effect on 3 parameters of Met S, but
gave an elaborate mechanism for their antiobesity effect including
enhanced leptin expression. Amongst the studies reported in this
review, limited studies assessed BP (Thota et al., 2014; Amin et al.,
2015a); whereas, most of them did not assess blood pressure in their
models, and therefore the studies which have either met 3 or 4 out of
5 parameters of MetS are majorly the ones which did not
assess BP in their animal models (Mounts et al., 2015). One
of the reasons for this could be that BP monitoring in
animals is technically challenging, and assessing it for
number of animals, which usually are 40–50 altogether, is
highly tedious and time consuming.
The other part of our review focussed on clinical trials in
the last 15 years which used polyherbal formulations for the
management of MetS. Amongst the combinations reviewed
the most effective considered were the ones which met
maximum MetS parameters. The maximum parameters
modified were 4 out of 5 by 3 combinations including Yiqi
Huazhuo Gushen herbal formula (Tian-zhan et al., 2019),
Yiqi Huaju Qingli Formula (Wang et al., 2013), and Sesame
oil and vitamin E combination (Farajbakhsh et al., 2019).
However, these studies were assessed for short period of time
ranging from 8 to 12 weeks, which may be helpful in
determining the acute effect but not long-term effect and
side-effects.
From this perspective a study by Yadav et al. (2014) is worth
mentioning who studied the effects of herbal combination
“Diabegon” till 1.5 years and monitored the effect on liver
and kidney parameters, which showed no toxic effects on
these organs. In fact, the combination reduced uric acid and
effectively reduced FBG, TG and increased HDL, although
BP was not monitored. Another worthy study in this regard
was controlled clinical trial which used Keishibukuryogan,
a traditional Japanese (Kampo) formula (Nagata et al.,
2012) in MetS patients in a cross over design. Although,
it did not reduce any MetS parameters, its main outcome
was improvement in endothelial function which has a
preventive role towards atherosclerosis. Such study
designs should be adopted for formulas which have
shown promising results in small scale studies.
Some studies design was flawed and therefore the effects
could not be validated. For instance, study by Yang et al.
(2014a) on MLD along with weekend fasting tested the
combination on MetS patients but no comparative control
was used. We could not determine whether the effect was due
to MLD or weekend fasting. Aims of the study were also not
clearly written in the write-up. Similarly, a combination of
nutraceuticals with dietary interventions very efficiently
reflected the improvement in MetS parameters to an extent
that the patients no longer fulfilled the MetS criteria after
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TABLE 5 | Summary of meta-analysis of polyherbal combinations used in Clinical studies in patients with MetS according to SPIDER model, concentration, quality control and chemical classifications reports.









































typhae, the rhizome of
oriental water plantain,
































































































































Quantitative CRP. Amin et al.
(2015b)
Yes No No

































TABLE 5 | (Continued) Summary of meta-analysis of polyherbal combinations used in Clinical studies in patients with MetS according to SPIDER model, concentration, quality control and chemical classifications reports.
































































































































































































TABLE 5 | (Continued) Summary of meta-analysis of polyherbal combinations used in Clinical studies in patients with MetS according to SPIDER model, concentration, quality control and chemical classifications reports.
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TABLE 5 | (Continued) Summary of meta-analysis of polyherbal combinations used in Clinical studies in patients with MetS according to SPIDER model, concentration, quality control and chemical classifications reports.


































































































Abbreviations: 24hTP, 24 h total urinary protein; 2hPPG, 2 h post prandial glucose; AST, aspartate aminotransferase; ALT, alanine transaminase; ALP, alkaline phosphatase; BP, blood pressure; BMI, body mass index; CDKAL  CDK5
Regulatory Subunit Associated Protein 1 Like 1); CETP, cholesteryl ester transfer protein; CRP, C-reactive protein; FBG: fasting blood glucose; FFA, free fatty acid; GLUT-4, glucose transporter 4; GGT, glutamyl-transferase; HC, hip
circumference; HDL-C, high density lipoproteins; HFD, high fat diet; HOMA-IR, homeostatic model assessment for insulin resistance; ICAM-1, intercellular adhesion molecules; IRS-1, Insulin receptor substrate 1; KKAy, cross between
diabetic KK and lethal yellow; LDL, low density lipoprotein; Monocyte chemoattractant protein-1; MAU/MA, microalbuminuria; MDA, malondialdehyde; NAFA, non-esterified fatty acids; NF-kB, Nuclear Factor kappa-light-chain-enhancer of
activated B cells; PI3K phosphoinositide 3-kinase SREBP, sterol regulatory element-binding transcription factor; PPAR-c/a, Peroxisome proliferator-activated receptor gamma/alpha; SD Rats, Sprague Dawley rats; SGOT, Serum glutamic
oxaloacetic transaminase; SGPT, Serum glutamic pyruvic transaminase; SOD, superoxide dismutase; TC, total cholesterol; TG, triglycerides; TNF, Tumor necrosis factor; vLDL, very low density lipoprotein; UACR, urea creatinine albumin

































TABLE 6 | Qualitative scoring of clinical trials.






















































Wang et al., 2019
(Tian-zhan et al.,
2019)
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Wang et al., 2007
(He et al., 2007)
1 1 1 1 1 1 1 N/A 1 2 http://www.jcimjournal.com/EN/
10.3736/jcim20070307












































small sample size, the magnitude of impact could not be
extrapolated and needs to be studied further. Some clinical
studies assessed only limited parameters of MetS and
therefore in terms of effectiveness those combinations are
considered as not so good. Nevertheless, that’s not completely
true, because the authors did not measure the remaining
parameters (He et al., 2007; Panahi et al., 2014; Panahi
et al., 2015). Reason for this could be that the main
objective of those studies was to explore additional
mechanisms of MetS. For instance, Panahi et al., (Panahi et al.,
2015) report curcuminoids to reduce 2 out of 5 MetS parameters
because they assessed only BP and BMI. Their main finding was
anti-inflammatory and antioxidant activities, whereas
antidyslipidemic effect was reported in their preceding study
(Panahi et al., 2014).
The current review has certain limitations. One of the factors
to be considered for future reviews should be to differentiate the
polyherbal combinations according to different ethnicities and
cultures in which the herb is famously used such as Asian,
Chinese and Japanese traditional medicine. The current review
can be used by researchers for idnetifying different polyherbal
combinations by considering which herbs could simultaneously
target many or all risk factors for MetS. For future studies some
known anti-obesity and/or antihypertensive herbs shall be
considered as an add-on with those polyherbal combinations
that predominantly exhibited anti-hyperglycaemic and anti-
dyslipidemic effect, to be able to manage multiple MetS
parameters simultaneously. This is one of the advantages of
such reviews that researchers could identify the missing targets
and add herb accordingly for future studies.
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